This was a prospective, observational cross-sectional study conducted at a tertiary care private hospital in India. The study was designed to comprehensively evaluate the prevalence, management strategies, and clinical outcomes of in-hospital hyperglycemia among adult inpatients. The study also explored the associations of metabolic biomarkers-fetuin-A and fibroblast growth factor-21 (FGF-21) as well as sarcopenic obesity and nutritional factors with clinical outcomes, including length of hospital stay (LOS), complications, and mortality. Institutional Ethics Committee approval was obtained prior to study initiation, and written informed consent was secured from all participants
Study Type
OBSERVATIONAL
Enrollment
362
Division Of Endocrinology & Diabetes
Gurgaon, Haryana, India
To determine the prevalence of hyperglycemia
To determine the prevalence of hyperglycemia and pre-existing or newly diagnosed type 2 diabetes mellitus (T2DM) among hospitalized patients
Time frame: 10 Days
Assess clinical outcomes associated with hyperglycemia
To assess clinical outcomes associated with hyperglycemia, including in-hospital complications, mortality, need for critical care support, and length of hospital stay (LOS)
Time frame: 10 Days
Prevalence of sarcopenic obesity
To assess the prevalence of sarcopenic obesity among diabetic and hyperglycemic patients, and to determine its association with metabolic dysfunction and adverse outcomes
Time frame: 10 Days
Analyze serum biomarker level fetuin-A
To analyze serum biomarker level fetuin-A and correlate them with severity of metabolic dysregulation .Serum fetuin-A levels were measured using commercially available enzyme-linked immunosorbent assay (ELISA) kits
Time frame: 10 Days
Analyze serum biomarker level FGF-21
To analyze serum biomarker levels FGF-21 and correlate them with severity of metabolic dysregulation.Serum FGF-21 levels were measured using commercially available enzyme-linked immunosorbent assay (ELISA) kits
Time frame: 10 Days
Analyze serum biomarker level FGF-21
To analyze serum biomarker levels FGF-21 and correlate them with liver fibrosis indices.Serum FGF-21 levels were measured using commercially available enzyme-linked immunosorbent assay (ELISA) kits
Time frame: 10 Days
Analyze serum biomarker level fetuin-A
To analyze serum biomarker level fetuin-A and correlate them with liver fibrosis indices .Serum fetuin-A levels were measured using commercially available enzyme-linked immunosorbent assay (ELISA) kits
Time frame: 10 Days
To assess Impact of diet
To assess the impact of adequacy of dietary on glycemic control and recovery, will measure the Sugar level at Before Breakfast,Before Lunch,Before Dinner
Time frame: 10 Days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.